Frontiers in Oncology最新文献

{"title":"Editorial: Integrating imaging techniques to enhance precision in cancer immunotherapy.","authors":"Jesus Pacheco-Torres","doi":"10.3389/fonc.2026.1819541","DOIUrl":"https://doi.org/10.3389/fonc.2026.1819541","url":null,"abstract":"","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1819541"},"PeriodicalIF":3.5,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aerobic glycolysis in bladder cancer: research advances and targeted therapy potential.","authors":"Mengyuan Pan, Tianyi Tao, Dehui Kong, Hua Gong","doi":"10.3389/fonc.2026.1799955","DOIUrl":"https://doi.org/10.3389/fonc.2026.1799955","url":null,"abstract":"<p><p>Bladder cancer (BCa) is one of the most common malignant tumors of the urinary system. Its frequent recurrence, high metastatic potential, and resistance to therapies pose major obstacles to achieving long-term patient survival. As a core feature of tumor metabolic reprogramming, aerobic glycolysis (the Warburg effect) plays an essential role in the development of BCa. Current studies indicate that key glycolytic enzymes such as hexokinase 2 (HK2), pyruvate kinase M2 (PKM2), and lactate dehydrogenase A (LDHA) are abnormally expressed in BCa. These alterations in enzyme activity not only directly reshape energy metabolism but also exert non-metabolic functions, regulating tumor cell proliferation and invasion. Simultaneously, the aberrant activation of signaling pathways such as PI3K/AKT/mTOR and HIF-1α further drives the glycolytic process. Moreover, the lactate produced through glycolysis leads to tumor microenvironment (TME) acidification, which facilitates extracellular matrix remodeling and immune evasion. In terms of treatment, strategies that directly target key glycolytic enzymes and indirectly intervene in the regulation of signaling pathways show promising application potential. Nevertheless, issues related to treatment-associated toxicity and the emergence of therapeutic resistance remain unresolved. This review systematically summarizes the characteristics of key enzymes in aerobic glycolysis, molecular regulatory mechanisms, and advancements in targeted therapy for BCa, aiming to provide new theoretical insights and directions for metabolic intervention and targeted therapy in BCa.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1799955"},"PeriodicalIF":3.5,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abdominal disseminated lesions following surgery for a testicular mucinous cystic neoplasm initially diagnosed as mucinous cystadenoma: a case report and literature review.","authors":"Junjie Yang, Weida Li, Jian Wang, Jianchang Li","doi":"10.3389/fonc.2026.1731890","DOIUrl":"https://doi.org/10.3389/fonc.2026.1731890","url":null,"abstract":"<p><p>This report describes a rare testicular mucinous cystic neoplasm in a 78-year-old man who underwent scrotal exploration and right radical orchiectomy. Histopathology of the resected specimen was interpreted as an ovarian-type mucinous cystadenoma with focal epithelial proliferation. Six months after surgery, follow-up imaging demonstrated multiple abdominal and peritoneal lesions suspicious for disseminated disease. Because the abdominal lesions were diagnosed radiologically and were not histologically sampled, metastatic disease could not be pathologically confirmed. In addition, immunohistochemical analysis of the orchiectomy specimen was not performed, and a gastrointestinal primary tumor was not definitively excluded by endoscopic evaluation. The case highlights the diagnostic challenges of distinguishing benign, borderline, malignant, and metastatic mucinous tumors involving the testis, and it emphasizes the importance of postoperative surveillance, comprehensive clinicopathologic correlation, immunohistochemistry, and exclusion of an extratesticular primary site.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1731890"},"PeriodicalIF":3.5,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: A case of non-secretory multiple myeloma presenting with eosinophilia: diagnostic challenges and a focused literature review.","authors":"Jirui Zhong, Xikun Liu, Jiduo Liu, Shanshan Xiao, Xuekui Gu, Zenghui Liu","doi":"10.3389/fonc.2026.1833556","DOIUrl":"https://doi.org/10.3389/fonc.2026.1833556","url":null,"abstract":"<p><p>We report a rare case of non-secretory multiple myeloma (NSMM) presenting with marked eosinophilia and considerable diagnostic difficulty. A 56-year-old man was admitted with recurrent low back pain of more than 10 years' duration that had rapidly worsened over the preceding 10 days, accompanied by diffuse pain and weight loss. Laboratory evaluation showed persistent eosinophilia, thrombocytopenia, elevated lactate dehydrogenase, and increased inflammatory markers. Imaging revealed multifocal osteolytic lesions involving the skull, vertebrae, ribs, and pelvis. However, serum and urine immunofixation electrophoresis were negative, qualitative urine Bence-Jones protein testing was negative, and repeated serum free light chain testing showed a normal κ/λ ratio, making the diagnosis particularly challenging. Bone marrow aspirate showed marked eosinophilia, and flow cytometry identified clonal plasma cells accounting for 6.1% of nucleated cells. Bone marrow biopsy with immunohistochemistry confirmed a plasma-cell neoplasm, while myeloma fluorescence <i>in situ</i> hybridization (FISH) revealed 1q21 gain/amplification together with chromosome 13-related abnormalities, including RB1 deletion and D13S319 abnormality. After exclusion of secondary and primary/clonal eosinophilic disorders, the patient was diagnosed with NSMM with eosinophilia. This case highlights the diagnostic challenge posed by the coexistence of marked eosinophilia and NSMM, which obscured the underlying plasma-cell malignancy despite repeatedly negative monoclonal protein studies. We also reviewed the limited literature on MM-associated eosinophilia to underscore the importance of integrating bone marrow findings, imaging, and cytogenetic evaluation in atypical cases.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1833556"},"PeriodicalIF":3.5,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma expression of long non-coding RNA <i>GAS5</i> and its prognostic significance in newly diagnosed multiple myeloma.","authors":"Anica Pravdic Divac, Natasa Tosic, Zorica Cvetkovic, Marko Radulovic, Teodora Karan-Djurasevic, Aleksandra Tomic, Irena Marjanovic, Natasa Stanisavljevic, Branka Zukic, Olivera Markovic","doi":"10.3389/fonc.2026.1791554","DOIUrl":"https://doi.org/10.3389/fonc.2026.1791554","url":null,"abstract":"<p><strong>Introduction: </strong>Long non-coding RNAs (lncRNAs) participate in pathogenesis, progression and therapy resistance in multiple myeloma (MM). Growth Arrest-Specific 5 (<i>GAS5</i>) is a lncRNA with a role in proliferation, invasion and metastasis in solid tumors, but prognostic significance in MM is unknown so far. Aim: The purpose of this study was to examine the expression pattern of <i>GAS5</i> lncRNA in plasma samples of MM patients and to evaluate its clinical and prognostic significance.</p><p><strong>Methods and material: </strong>73 newly diagnosed patients with MM and 16 healthy volunteers were recruited from Clinical Hospital Centre (CHC) \"Bežanijska Kosa\" and CHC \"Zemun\" in the period from July 2020 to December 2024. Blood samples were collected before starting therapy. Demographic, laboratory and clinical parameters, prognostic score, overall response rate, progression free survival (PFS) and overall survival (OS) were analyzed. Relative quantification analysis of the <i>GAS5</i> expression level was performed by RQ-PCR methodology with the <i>GAPDH</i> gene as endogenous control and by using the comparative ddCt method with control samples as a calibrator.</p><p><strong>Results: </strong>No significant difference was found between plasma expression <i>GAS5</i> in MM patients (median 0.833, range 0.013-3.678) and <i>GAS5</i> expression in healthy control samples (median 1, range 0.49-2.668) (p=0.116). In multivariate analysis with PFS as the dependent variable, higher <i>GAS5</i> expression and advanced age were associated with shorter time to progression, while higher R2-ISS score, advanced age and occurrence of relapse/progression of disease were independent prognostic factors for survival in our group of patients.</p><p><strong>Conclusion: </strong>This is the first study showing prognostic potential of circulating lncRNA <i>GAS5</i> in the MM patients. Patients with MM had a slightly lower <i>GAS5</i> expression compared to control samples, this was, nevertheless, without statistical significance. In patients with higher GAS5 expression disease progression occurred earlier compared to patients with lower expression. To establish <i>GAS5</i> as a robust biomarker in MM, future studies should focus on larger patient cohorts to validate its expression within the bone marrow niche and its specific association with high-risk 'double-hit' cytogenetic aberrations and glucocorticoid resistance.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1791554"},"PeriodicalIF":3.5,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between myeloid skewing and colorectal cancer risk in the Framingham Heart Study.","authors":"Lisa Ek Orloff, Michael De Lisio","doi":"10.3389/fonc.2026.1773537","DOIUrl":"https://doi.org/10.3389/fonc.2026.1773537","url":null,"abstract":"<p><strong>Introduction: </strong>Differential regulation of myelopoiesis may contribute to divergent colorectal cancer (CRC) risk profiles associated with obesity and physical activity; however, this relationship has not been examined in humans. This study explored the relationship between myeloid skewing (monocyte-to-lymphocyte ratio), physical activity, obesity, and CRC risk in a retrospective cohort.</p><p><strong>Methods: </strong>From the Framingham study cohort, myeloid skewing was compared across BMI categories, waist circumference quartiles, and physical activity index (PAI) quintiles. Among participants who eventually received a CRC diagnosis, Cox proportional hazards models evaluated baseline circulating myeloid skewing as a predictor of incident CRC, adjusted for covariates.</p><p><strong>Results: </strong>Within the total study population (n = 5037), myeloid skewing increased across BMI categories, and waist circumference quartiles (P <.001), and decreased in the highest vs lowest PAI (P <.01). In the predictive cohort (non-CRC, n = 818; CRC, n = 16), continuous Cox models (per 1-SD increase in myeloid skewing) showed hazard ratios (HR) ranging from 1.08 to 1.37. Associations were statistically significant in BMI, waist circumference, BMI and waist circumference, PAI, diabetes, sex, and smoking adjusted models (HRs 1.30-1.37; P <.05), but were attenuated and not statistically significant in age, age and sex, and medication adjusted models (HRs 1.08-1.28; P >.05).</p><p><strong>Discussion: </strong>Obesity and lower physical activity were associated with higher myeloid skewing, and higher myeloid skewing was associated with increased incident CRC hazard across several adjusted Cox models. These findings highlight myeloid skewing as a candidate marker linking adiposity and physical inactivity to CRC risk and justify prospective validation in larger cohorts.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1773537"},"PeriodicalIF":3.5,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic symbiosis and competition: the dual nature of TAM-tumor cell cross-talk in tumor progression.","authors":"Chaokai Ba, Shizheng Tong, Zefan Wang, Huiting Zhu, Shenxian Qian","doi":"10.3389/fonc.2026.1821192","DOIUrl":"https://doi.org/10.3389/fonc.2026.1821192","url":null,"abstract":"<p><p>Cancer cells and tumor associated macrophages (TAMs) engage in a sophisticated metabolic symbiosis within the tumor microenvironment (TME), where reciprocal metabolite exchange drives immune evasion and malignant progression. This review posits that TAMs functional plasticity is not merely a consequence but a driver of tumor fitness, governed by extensive metabolic rewiring. We dissect the mechanistic underpinnings of this \"metabolic dialogue,\" focusing on the convergence of glycolytic flux, the lactate shuttle, amino acid catabolism, lipid reprogramming, hypoxia-induced adaptations, and TCA cycle anaplerosis. Beyond delineating these pathways, we critically evaluate emerging therapeutic paradigms that target these metabolic nodes, advocating for precision interventions capable of disrupting this pro-tumorigenic alliance while restoring immune surveillance.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1821192"},"PeriodicalIF":3.5,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.","authors":"Hao Zhang, Shenbao Hu, Niya Kong","doi":"10.3389/fonc.2026.1819766","DOIUrl":"https://doi.org/10.3389/fonc.2026.1819766","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the risk factors for cardiotoxicity induced by trastuzumab in human epidermal growth factor receptor 2 (HER2) -positive breast cancer patients and provide a basis for early clinical intervention.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 298 HER2-positive breast cancer patients treated with trastuzumab. Clinical data including age, history of cardiovascular disease, combined chemotherapy regimens, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, and baseline left ventricular ejection fraction (LVEF) were collected. Multivariate logistic regression was used to identify independent risk factors for cardiotoxicity.</p><p><strong>Results: </strong>A total of 65 patients (21.8%) developed cardiotoxicity. Multivariate analysis showed that age ≥60 years (OR = 1.97, 95%CI: 1.21-3.22), history of hypertension (OR = 2.10, 95%CI: 1.24-3.56), combined anthracycline therapy (OR = 3.06, 95%CI: 1.67-5.62), baseline NT-proBNP ≥200 pg/ml (OR = 2.34, 95%CI: 1.35-4.05), and baseline LVEF ≤55% (OR = 2.51, 95%CI: 1.42-4.43) were independent risk factors for trastuzumab-induced cardiotoxicity (all P < 0.05).</p><p><strong>Conclusion: </strong>These findings enable risk stratification before trastuzumab initiation. Future research should validate a predictive model incorporating these factors and assess cardioprotective strategies, thereby translating risk assessment into actionable protocols to optimize cardiac safety without compromising oncologic outcomes.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1819766"},"PeriodicalIF":3.5,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between 12 composite inflammatory indices and postoperative complications in colorectal cancer surgery: a two-center retrospective study.","authors":"Chunpeng Pan, Jiwei Yu, Shuai Huang, Shoulian Wang, Xiaochun Ni, Haibo Wang, Chihao Zhang, Fan Xiao","doi":"10.3389/fonc.2026.1808454","DOIUrl":"https://doi.org/10.3389/fonc.2026.1808454","url":null,"abstract":"<p><strong>Background: </strong>Postoperative complications (POCs) remain a major challenge in colorectal cancer (CRC) surgery. Easily accessible composite inflammatory indices derived from routine blood tests hold promise for preoperative risk stratification, but their comparative predictive value for POCs is unclear.</p><p><strong>Methods: </strong>We conducted a two-center, retrospective study of 1331 patients who underwent radical CRC surgery between January 2021 to October 2025. The associations between preoperative composite inflammatory indices and the complications after surgery were evaluated using logistic regression. Their predictive discriminative performances were further assessed and compared using receiver operating characteristic (ROC) curve analysis, with the areas under the curve (AUC) compared by DeLong's test.</p><p><strong>Results: </strong>The complication rate was 17.2% (229/1331). Patients with complications exhibited a significantly more pronounced pro-inflammatory and immunosuppressive preoperative profile across all indices (all <i>P</i> < 0.05). After adjustment, the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-lymphocyte ratio (CLR), and systemic inflammation response index (SIRI) were identified as the strongest independent predictors, with the highest quartile (Q4) conferring substantially increased risks (OR for SII: 7.51; for NLR: 5.86; for CLR: 2.24; for SIRI: 2.99; all <i>P</i>-trend <0.05). ROC analysis confirmed SII as the best single predictor (AUC: 0.738). A combined model integrating SII, NLR, CLR, and SIRI achieved superior discriminative ability (AUC: 0.792), significantly outperforming any single index (all <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The SII, NLR, CLR and SIRI, are strongly associated with the risk of POCs after CRC surgery. A model combining these four indices provides superior predictive performance.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1808454"},"PeriodicalIF":3.5,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors.","authors":"Antoine Italiano, Teresa García Manrique, Enrique Grande Pulido, Katie Kerrigan, Aude Fléchon, Julia Martínez Pérez, Bogdan Żurawski, Muhammad Furqan, Oscar Juan-Vidal, Ulka Vaishampayan, Charlene Fares, Bruno Fang, Brian Vicuna, Laurent Greillier, Vivek Subbiah, Mei Dong, Kai Song, Yiran Zhang, Young Kim, Luis Paz-Ares","doi":"10.3389/fonc.2026.1786385","DOIUrl":"https://doi.org/10.3389/fonc.2026.1786385","url":null,"abstract":"<p><strong>Background: </strong>Novel treatments are needed to improve the poor prognosis of metastatic cancers. The ELEVATE Lung&UC study evaluated magrolimab plus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC), metastatic small cell lung cancer (mSCLC), and metastatic urothelial carcinoma (mUC).</p><p><strong>Methods: </strong>This phase II, open-label, multi-arm study enrolled patients who had received 1-2 (mNSCLC, mSCLC) or 2-3 prior lines of therapy (mUC) in the locally advanced/metastatic setting. A safety run-in (SRI) cohort (mNSCLC/mSCLC/mUC) followed by a phase II cohort (three groups: mNSCLC, mSCLC, mUC) were planned. Primary endpoints were incidence of treatment-emergent adverse events (TEAEs; SRI and phase II) and objective response rate (ORR; phase II).</p><p><strong>Results: </strong>The SRI cohort (n = 9) had no dose-limiting toxicities. In phase II (mNSCLC, 29 patients; mSCLC, 42 patients; mUC, 26 patients), ORRs were 17.2% (mNSCLC), 4.8% (mSCLC), and 3.8% (mUC). Grade ≥3 magrolimab-related TEAE rates were 48.3% (mNSCLC), 47.6% (mSCLC), and 57.7% (mUC). A fatal TEAE suspected as magrolimab related (intracranial hemorrhage) occurred in one patient with mSCLC and brain metastasis (phase II). The study was closed early, which limited the interpretation of results due to short follow-up and limited endpoint maturity.</p><p><strong>Discussion: </strong>Adding magrolimab to docetaxel had manageable toxicity but no meaningful improvement in efficacy. These results provide insight into the safety and efficacy of anti-CD47-containing therapies and reinforce the need for treatments that address the unmet needs of patients with previously treated metastatic solid tumors.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1786385"},"PeriodicalIF":3.5,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}